MEDI4736 combinations in metastatic renal cell carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 01 Aug 2016
At a glance
- Drugs Durvalumab (Primary) ; Savolitinib; Tremelimumab
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CALYPSO
- Sponsors AstraZeneca
- 01 Aug 2016 According to Chi-Med and AstraZeneca media release, first patient has been dosed in phase 1b part during Q2 16 and estimated completion date of the trial is Q4 2019.
- 23 Jun 2016 New trial record
- 21 Jun 2016 Status changed from not yet recruiting to recruiting.